4//SEC Filing
Apeiron Investment Group Ltd. 4
Accession 0001193125-25-228361
CIK 0001840904other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 4:18 PM ET
Size
9.6 KB
Accession
0001193125-25-228361
Insider Transaction Report
Form 4
Angermayer Christian
Director10% Owner
Transactions
- Conversion
Convertible Notes
2025-09-30−147,950→ 0 total(indirect: By Apeiron Investment Group Ltd.)From: 2024-04-15Exp: 2025-09-30→ Common Shares (2,367,200 underlying) - Conversion
Common Shares
2025-09-30+2,367,200→ 53,412,414 total(indirect: By Apeiron Investment Group Ltd.)
Holdings
- 1,799,302(indirect: By Apeiron Presight Capital Fund II, L.P.)
Common Shares
Apeiron Investment Group Ltd.
10% Owner
Transactions
- Conversion
Common Shares
2025-09-30+2,367,200→ 53,412,414 total(indirect: By Apeiron Investment Group Ltd.) - Conversion
Convertible Notes
2025-09-30−147,950→ 0 total(indirect: By Apeiron Investment Group Ltd.)From: 2024-04-15Exp: 2025-09-30→ Common Shares (2,367,200 underlying)
Holdings
- 1,799,302(indirect: By Apeiron Presight Capital Fund II, L.P.)
Common Shares
Footnotes (2)
- [F1]The conversion price for the Convertible Notes is EUR 17.00 per note.
- [F2]The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.
Documents
Issuer
ATAI Life Sciences N.V.
CIK 0001840904
Entity typeother
IncorporatedMalta
Related Parties
1- filerCIK 0001845711
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 4:18 PM ET
- Size
- 9.6 KB